Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00720629 · OUTCOME

Incidence of Rituximab Response to Reactivated EBV Without PTLD

Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation · Source last updated 2014-07-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
100 days

What was measured

Participants who developed plasma EBV-DNA of \>1000 copies/mL on any tests received rituximab. Incidence of Rituximab Response: Reactivated EBV participants whose plasma titers cleared after rituximab, without post-transplant lymphoproliferative disorder (PTLD).

Analysis population: Reactivated EBV participants

Groups in this outcome

First Study Stage: Study Treatment

Visilizumab, Tacrolimus and Methotrexate. All participants.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
First Study Stage: Study Treatment6

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
First Study Stage: Study Treatment6Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        6
denoms
  1. counts
    1. group Id
      OG000
      value
      6
    units
    Participants
description
Participants who developed plasma EBV-DNA of \>1000 copies/mL on any tests received rituximab. Incidence of Rituximab Response: Reactivated EBV participants whose plasma titers cleared after rituximab, without post-transplant lymphoproliferative disorder (PTLD).
groups
  1. description
    Visilizumab, Tacrolimus and Methotrexate. All participants.
    id
    OG000
    title
    First Study Stage: Study Treatment
param Type
NUMBER
population Description
Reactivated EBV participants
reporting Status
POSTED
time Frame
100 days
title
Incidence of Rituximab Response to Reactivated EBV Without PTLD
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice